International study shows wide differences in 5-year survival rates across the globe
the ONA take:
According to a new study published in the journal The Lancet, there are very large differences in 5-year survival among patients with cancer between 67 countries.
For the CONCORD-2 study, researchers used patient data from 279 cancer registries and identified 25.7 million patients with cancer diagnosed with one of the 10 most common cancers, as well as 75,000 children diagnosed with acute lymphoblastic leukemia (ALL) between 1995 and 2009.
Results showed that pediatric patients with ALL had various different 5-year survival rates depending upon what country they reside in. Patients from Indonesia, Jordan, Lesotho, Mongolia, and Tunisia had a 5-year survival rate between 16% and 50%, while patients in Austria, Belgium, Canada, Germany, and Norway had a 5-year survival rate over 90%.
Among the 10 most common cancers, Israel and Ecuador had the highest survival for colon cancer (≥68%); Cyprus, Iceland, and Japan had the highest for rectal cancer (≥70%); and Australia, Brazil, Canada, Cyprus, Israel, Japan, the U.S. and many European countries had the highest survival for breast cancer (≥85%). Mongolia had the lowest survival for breast, colon, and rectal cancers. In Europe, European Russia had the lowest survival for those three cancers.
There are very large differences in 5-year survival among patients with cancer between 67 countries.
- Ixazomib, a New PI, Offers Improved Efficacy With Acceptable Toxicity Profile for Relapsed/Refractory Multiple Myeloma
- Acupuncture May Improve Fatigue in Patients with Lung Cancer
- "Light" Cigarettes and Cancer Risk (Fact Sheet)
- A Review of CDK4/6 Toxicities and Interactions Management in Breast Cancer
- Vitamin D3 Supplementation Has No Impact on Breast Density Percentage, Breast Cancer Risk
- Dexamethasone-Induced Hiccups in Chemotherapy May be Prevented by Rotating to Methylprednisolone
- New Evidence Shows Metastases May Spread Independently of Lymph Nodes
- Long Term Survivors of Prostate Cancer Express Treatment Decision Regret for Up to 15 Years
- FDA Expands Clearance for Cooling Cap Use With Chemotherapy for Solid Tumors
- Recommendations for Vaccine Administration During Chemotherapy
- Risk for Prostate Cancer Not Associated With Vasectomy, Meta-analysis Affirms
- Disease-Free Survival After Breast Cancer Comparable With Exemestane, Sequential Tamoxifen/Exemestane
- Treating the Other "Patient": Depressive Symptoms Are Predictive of Declining Physical Health in Caregivers
- Oropharyngeal Mucositis Pain Effectively Relieved With Indomethacin Oral Spray
- Opioids Overprescribed in Patients Undergoing Surgery
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|